Advertisement

Medicinal Chemistry Research

, Volume 19, Issue 3, pp 211–219 | Cite as

Three-dimensional common-feature hypotheses for hypoglycemic flavonyl-2,4-thiazolidinedione derivatives

  • Ilkay YildizEmail author
  • Oya Bozdag-Dundar
Original Research

Abstract

Three-dimensional pharmacophore hypotheses were built from a set of seven antidiabetic agents. Among the ten commonly featured models generated by program Catalyst/HipHop, a hypothesis including four hydrogen-bond acceptors (HBAs) and two hydrophobic aromatics (HpArs) features was considered to be important in evaluating the hypoglycemic activity. The most active 3-ethyl-5-[3′-(4H-4-oxo-1-benzopyran-2-yl)benzylidene]-2,4-thiazolidinedione (4b) mapped well onto all the HBAs and HpArs features of the hypothesis.

Keywords

Pharmacophore analysis HipHop Hypoglycemic agents 2,4-thiazolidinediones 2,4-imidazolidinediones 2-thiohydantoin Flavone 

References

  1. Barnum D, Greene J, Smellie A, Sprague PJ (1996) Identification of common functional configurations among molecules. J Chem Inf Comput Sci 36:563–571PubMedGoogle Scholar
  2. Bozdağ O, Verspohl EJ, Ertan R (2000a) Synthesis and hypoglycemic activity of some new flavone derivatives. 2nd Communication: 4′-flavonyl-2, 4-thiazolidinediones. Arzneim-Forsch/Drug Res 50(I):539–543Google Scholar
  3. Bozdağ O, Verspohl EJ, Ertan R (2000b) Synthesis and hypoglycemic activity of some new flavone derivatives. 3rd Communication: 3′-flavonyl-2, 4-thiazolidinediones. Arzneim-Forsch/Drug Res 50(II):626–630Google Scholar
  4. Clement OO, Mehl AT (2000) HipHop: pharmacophore based on multiple common-feature alignments. In: Guner OF (ed) Pharmacophore perception, development, and use in drug design. IUL, San Diego, pp 69–84Google Scholar
  5. DeFronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM. Diabetes Care 15:318–368CrossRefPubMedGoogle Scholar
  6. Food and Drug Administration (2000) Resulin to be withdrawn from the market. HHS. http://www.fda.gov/medwatch/safety/2000; Accessed 21 Mar 2000
  7. Fujita T, Sugiyama Y, Takemoti S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z (1983) Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2, 4-dione (ADD-3878, U-63, 287, Ciglitazone), a new antidiabetic agent. Diabetes 32:804–810CrossRefPubMedGoogle Scholar
  8. Greene J, Kahn SD, Savoj H, Sprague PW, Teig SL (1994) Chemical function queries for 3D database search. J Chem Inf Comput Sci 34:1297–1308Google Scholar
  9. Hirashima A, Morimoto M, Kuwano E, Taniguchi E, Eto M (2002) Three-dimensional common-feature hypotheses for octopamine agonist 2-(arylimino)imidazolidines. Bioorg Med Chem 10:117–123CrossRefPubMedGoogle Scholar
  10. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I (1991) Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083–1086CrossRefPubMedGoogle Scholar
  11. Smellie A, Teig SL, Towbin P (1994) Poling: promoting conformational variation. J Comp Chem 16:171–187CrossRefGoogle Scholar
  12. Smellie A, Kahn SD, Teig SL (1995a) Analysis of conformational coverage. 1. Validation and estimation of coverage. J Chem Inf Comp Sci 35:285–294Google Scholar
  13. Smellie A, Kahn SD, Teig SL (1995b) Analysis of conformational coverage. 2. Applications of conformational models. J Chem Inf Comp Sci 35:295–304Google Scholar
  14. Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H (1990) Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]2, 4-thiazolidinediones. Arzneim Forsch/Drug Res 40:37–42Google Scholar
  15. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193–203CrossRefPubMedGoogle Scholar
  16. Yki-Järvinen H (1994) Pathogenesis of non-insulin dependent diabetes mellitus. Lancet 343:91–95CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Boston 2009

Authors and Affiliations

  1. 1.Faculty of Pharmacy, Department of Pharmaceutical ChemistryAnkara UniversityAnkaraTurkey

Personalised recommendations